Johnson & Johnson Appoints Tom Cavanaugh as Successor to Jennifer Taubert

Johnson & Johnson has announced that Jennifer Taubert will retire as EVP, Worldwide Chairman, Innovative Medicine after a 21-year tenure in September 2026. Tom Cavanaugh has been appointed to succeed her, bringing almost three decades of experience in biopharmaceuticals and direct experience in Johnson & Johnson's oncology and immunology franchises.

The change affects the company's key pharmaceutical segment and may shape future priorities in research, development, and commercialization. Over the past year, Johnson & Johnson's stock price is up 53.0%, and up 60.7% over three years and 68.9% over five years.

Cavanaugh's track record in oncology, immunology, and global commercial strategy may help Johnson & Johnson consolidate recent moves in cancer and cell therapy and align future deals with existing strengths. Continuity from promoting an internal executive who already runs the largest commercial region could support consistent execution on Johnson & Johnson's long-term growth plans across Innovative Medicine and MedTech.